Abstract
The four EU countries analysed in this report - France, Italy, Portugal, Spain
- are expected to deliver significant double digit growth over the next 5
years and present stable, regulated operating environments with excellent
prospects.
The many generic companies and investors looking to Asian and Latin American
markets for generic drug market growth could be missing a trick! The four EU
countries analysed in this report are expected to deliver significant double
digit growth over the next 5 years and present stable, regulated operating
environments with excellent prospects.
Key Areas Addressed:
- 5-year market forecasts to 2012 for the pharmaceutical and generic drug
markets
- Analysis of market trends and outlook of key developments
- Domestic production and review of leading companies
- Regulatory environment
- Health provision and plans
THIS REPORT ANSWERS KEY QUESTIONS
- Which therapy sector accounted for the greatest part of the Spanish
generics market in 2006?
- What measures are in place to reduce generic prices in Portugal?
- How might developments in the French reference pricing system affect the
generics market?
- What developments with supplementary protection certificates will
positively affect the Italian generics market after 2010?
- What are the 8 leading active ingredients to lose patent protection in
Italy in 2007?
- How has generic pravastatin fared in the French statin market against
simvastatin?
View Cart
